Cardiac events during treatment with proteasome inhibitor therapy for multiple myeloma.

Chen, John H; Lenihan, Daniel J; Phillips, Sharon E; Harrell, Shelton L; Cornell, Robert F

Chen, John H; Lenihan, Daniel J; Phillips, Sharon E; Harrell, Shelton L; Cornell, Robert F.

Afiliação

Chen JH; 1Department of Medicine, Division of Hematology-Oncology, Vanderbilt University Medical Center, 2220 Pierce Avenue, 777 PRB, Nashville, TN 37232 USA.
Lenihan DJ; 2Department of Medicine, Division of Cardio-Oncology, Vanderbilt Heart & Vascular Institute, 1215 21st Avenue South, 5209 MCE, Nashville, TN 37232 USA.
Phillips SE; 3Department of Biostatistics, Division of Cancer Biostatistics, Vanderbilt University Medical Center, 2220 Pierce Avenue, 571 PRB, Nashville, TN 37232 USA.
Harrell SL; 1Department of Medicine, Division of Hematology-Oncology, Vanderbilt University Medical Center, 2220 Pierce Avenue, 777 PRB, Nashville, TN 37232 USA.
Cornell RF; 1Department of Medicine, Division of Hematology-Oncology, Vanderbilt University Medical Center, 2220 Pierce Avenue, 777 PRB, Nashville, TN 37232 USA.

Cardiooncology ; 3: 4, 2017.

Article em En | MEDLINE | ID: mdl-32154000

Palavras-chave

Bortezomib; Cardiotoxicity; Carfilzomib; Myeloma; Proteasome inhibitors; Risk factors

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies / Risk_factors_studies Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google